Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia

Mutations in the fms-like tyrosine kinase 3 (FLT3) gene are detected in approximately one-third of patients with newly diagnosed acute myeloid leukemia (AML). These consist of the more common FLT3-internal tandem duplication (ITD) in approximately 20–25% of AML cases, and point mutations in the tyro...

Descripción completa

Detalles Bibliográficos
Autores principales: Short, Nicholas J., Kantarjian, Hagop, Ravandi, Farhad, Daver, Naval
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378516/
https://www.ncbi.nlm.nih.gov/pubmed/30800259
http://dx.doi.org/10.1177/2040620719827310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378516/
https://www.ncbi.nlm.nih.gov/pubmed/30800259
http://dx.doi.org/10.1177/2040620719827310

Ejemplares similares